Our results indicate that CCR4 antagonists can protect from aspergillosis and allergic bronchopulmonary aspergillosis (ABPA) in susceptible mice and in a murine model of cystic fibrosis (CF), thus extending the clinical indications for therapeutic development of CCR4 targeting drugs. Here, CCR4 is linked to allergic bronchopulmonary aspergillosis.